Cardlytics Announces Fourth Quarter and Fiscal Year 2020 Financial Results

In this article:

ATLANTA, March 01, 2021 (GLOBE NEWSWIRE) -- Cardlytics, Inc., (NASDAQ: CDLX), a purchase intelligence platform that makes marketing more relevant and measurable, today announced financial results for the fourth quarter and fiscal year ended December 31, 2020. Supplemental information is available on the Investor Relations section of the Cardlytics' website at http://ir.cardlytics.com/.

“We are pleased to announce strong fourth quarter results that exceeded our prior guidance for both revenue and billings,” said Lynne Laube, CEO & Co-Founder of Cardlytics. “As previously announced, we look forward to welcoming Dosh’s talented team and partners to Cardlytics. Dosh’s technology is extremely complementary to the long-term financial institution integrations and substantial scale we’ve built over the past thirteen years.”

“As expected, we continued to see month over month increases in billings and revenue through the end of the year,” said Andy Christiansen, CFO of Cardlytics. “We look forward to returning to growth in 2021 and see many exciting organic and inorganic investment opportunities to support long-term growth in shareholder value.”

Fourth Quarter 2020 Financial Results

  • Total revenue was $67.1 million, a decrease of (3.2)%, compared to $69.3 million in the fourth quarter of 2019.

  • Net loss attributable to common stockholders was $(6.8) million, or $(0.24) per diluted share, based on 27.7 million weighted-average common shares outstanding, compared to a net income attributable to common stockholders of $3.4 million, or $0.12 per diluted share, based on 26.1 million weighted-average common shares outstanding in the fourth quarter of 2019.

  • Non-GAAP net loss was $(1.5) million, or $(0.05) per diluted share, based on 27.7 million weighted-average common shares outstanding, compared to a non-GAAP net income of $5.2 million, or $0.18 per diluted share, based on 28.1 million weighted-average common shares outstanding in the fourth quarter of 2019.

  • Billings, a non-GAAP metric, was $94.0 million, a decrease of (6.9)%, compared to $100.9 million in the fourth quarter of 2019.

  • Adjusted contribution, a non-GAAP metric, was $29.7 million, a decrease of (4.4)%, compared to $31.0 million in the fourth quarter of 2019.

  • Adjusted EBITDA, a non-GAAP metric, was a gain of $4.5 million, a decrease of $(2.4) million, compared to a gain of $6.9 million in the fourth quarter of 2019.

Fiscal Year 2020 Financial Results

  • Total revenue was $186.9 million, a decrease of (11.2)%, compared to $210.4 million in 2019.

  • Net loss attributable to common stockholders was $(55.4) million, or $(2.04) per diluted share, based on 27.2 million weighted-average common shares outstanding, compared to a net loss attributable to common stockholders of $(17.1) million, or $(0.72) per diluted share, based on 23.7 million weighted-average common shares outstanding in 2019.

  • Non-GAAP net loss was $(23.3) million, or $(0.85) per diluted share, based on 27.2 million weighted-average common shares outstanding, compared to a loss of $(1.9) million, or $(0.08) per diluted share, based on 23.7 million weighted-average common shares outstanding in 2019.

  • Billings, a non-GAAP metric, was $263.4 million, a decrease of (16.7)%, compared to $316.1 million in 2019.

  • Adjusted contribution, a non-GAAP metric, was $82.2 million, a decrease of (13.7)%, compared to $95.2 million in 2019.

  • Adjusted EBITDA, a non-GAAP metric, was a loss of $(7.8) million, a decrease of $(13.8) million, compared to a gain of $6.1 million in 2019.

Key Metrics

  • Average FI MAUs in the quarter were 163.6 million, an increase of 22.6%, compared to 133.4 million in the fourth quarter of 2019. For full year 2020, average FI MAUs were 155.8 million, an increase of 27.1%, compared to 122.6 million in 2019.

  • ARPU in the quarter was $0.41, a decrease of (21.2)%, compared to $0.52 in the fourth quarter of 2019. For full year 2020, ARPU was $1.20, an decrease of (30.2)%, compared to $1.72 in 2019.

Definitions of FI MAUs and ARPU are included below under the caption “Non-GAAP Measures and Other Performance Metrics.”

First Quarter and Fiscal Year 2021 Financial Expectations

Cardlytics anticipates billings, revenue, and adjusted contribution to be in the following ranges (in millions):

Q1 2021 Guidance

FY 2021 Guidance

Billings(1)

$67.0 - $75.0

$360.0 - $400.0

Revenue

$47.0 - $53.0

$250.0 - $275.0

Adjusted contribution(2)

$20.0 - $24.0

$110.0 - $125.0

(1) A reconciliation of billings to GAAP revenue on a forward-looking basis is presented below under the heading "Reconciliation of Forecasted GAAP Revenue to Billings."
(2) A reconciliation of adjusted contribution to GAAP gross profit on a forward-looking basis is not available without unreasonable efforts due to the high variability, complexity and low visibility with respect to the items excluded from this non-GAAP measure.

Earnings Teleconference Information

Cardlytics will discuss its fourth quarter and fiscal year 2020 financial results during a teleconference today, March 1, 2021, at 8:00 AM ET / 5:00 AM PT. The conference call can be accessed at (866) 385-4179 (domestic) or (210) 874-7775 (international), conference ID# 6256317. A replay of the conference call will be available through 11:00 AM ET / 8:00 AM PT on March 8, 2021 at (855) 859-2056 (domestic) or (404) 537-3406 (international). The replay passcode is 6256317. The call will also be broadcast simultaneously at http://ir.cardlytics.com/. Following the completion of the call, a recorded replay of the webcast will be available on Cardlytics’ website.

About Cardlytics

Cardlytics (NASDAQ: CDLX) uses purchase intelligence to make marketing more relevant and measurable. We partner with financial institutions to run their banking rewards programs that promote customer loyalty and deepen banking relationships. In turn, we have a secure view into where and when consumers are spending their money. We use these insights to help marketers identify, reach, and influence likely buyers at scale, as well as measure the true sales impact of marketing campaigns. Headquartered in Atlanta, Cardlytics has offices in London, New York, San Francisco and Visakhapatnam. Learn more at www.cardlytics.com.

Cautionary Language Concerning Forward-Looking Statements:

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to our financial guidance for the first quarter and full year of 2021, future growth, potential benefits of the acquisition of Dosh, and achievement of long-range goals. These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "intend," or variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control.

Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: risks related to the uncertain impacts that COVID-19 may have on our business, financial condition, results of operations; unfavorable conditions in the global economy and the industries that we serve; our quarterly operating results have fluctuated and may continue to vary from period to period; our ability to sustain our revenue growth and billings; risks related to our substantial dependence on our Cardlytics Direct product; risks related to our substantial dependence on JPMorgan Chase Bank, National Association (“Chase”), Bank of America, National Association ("Bank of America") and a limited number of other financial institution (“FI”) partners; the timing of the phased launch of the Cardlytics platform by U.S. Bank; risks related to our ability to maintain relationships with Chase, Wells Fargo and Bank of America; the amount and timing of budgets by marketers, which are affected by budget cycles, economic conditions and other factors, including the impact of the COVID-19 pandemic; our ability to generate sufficient revenue to offset contractual commitments to FIs; our ability to attract new FI partners and maintain relationships with bank processors and digital banking providers; our ability to maintain relationships with marketers; our ability to adapt to changing market conditions, including our ability to adapt to changes in consumer habits, negotiate fee arrangements with new and existing FIs and retailers, and develop and launch new services and features; and other risks detailed in the “Risk Factors” section of our Form 10-K filed with the Securities and Exchange Commission on March 1, 2021 and in subsequent periodic reports that we file with the Securities and Exchange Commission. Past performance is not necessarily indicative of future results.

The forward-looking statements included in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Non-GAAP Measures and Other Performance Metrics

To supplement the financial measures presented in our press release and related conference call or webcast in accordance with generally accepted accounting principles in the United States (“GAAP”), we also present the following non-GAAP measures of financial performance: billings, adjusted contribution, adjusted EBITDA, adjusted FI Share and other third party costs, non-GAAP net (loss) income and non-GAAP (loss) income per share as well as certain other performance metrics, such as FI monthly active users (“FI MAUs”) and average revenue per user (“ARPU”).

A “non-GAAP financial measure” refers to a numerical measure of our historical or future financial performance or financial position that is included in (or excluded from) the most directly comparable measure calculated and presented in accordance with GAAP in our financial statements. We provide certain non-GAAP measures as additional information relating to our operating results as a complement to results provided in accordance with GAAP. The non-GAAP financial information presented herein should be considered in conjunction with, and not as a substitute for or superior to, the financial information presented in accordance with GAAP and should not be considered a measure of liquidity. There are significant limitations associated with the use of non-GAAP financial measures. Further, these measures may differ from the non-GAAP information, even where similarly titled, used by other companies and therefore should not be used to compare our performance to that of other companies.

We have presented billings, adjusted contribution, adjusted EBITDA, adjusted FI Share and other third party costs, non-GAAP net (loss) income and non-GAAP net (loss) income per share as non-GAAP financial measures in this press release. Billings represents the gross amount billed to marketers for advertising campaigns in order to generate revenue. Billings is reported gross of both Consumer Incentives and FI Share. Our GAAP revenue is recognized net of Consumer Incentives and gross of FI Share. We define adjusted contribution as a measures by which revenue generated from our marketers exceeds the cost to obtain the purchase data and the digital advertising space from our FI partners. Adjusted contribution demonstrates how incremental marketing spend on our platform generates incremental amounts to support our sales and marketing, research and development, general and administration and other investments. Adjusted contribution is calculated by taking our total revenue less our FI Share and other third-party costs exclusive of a non-cash equity expense and deferred FI implementation costs, which are non-cash costs. Adjusted contribution does not take into account all costs associated with generating revenue from advertising campaigns, including sales and marketing expenses, research and development expenses, general and administrative expenses and other expenses, which we do not take into consideration when making decisions on how to manage our advertising campaigns. We define adjusted EBITDA as our net (loss) income before income tax benefit; interest expense, net; depreciation and amortization expense; stock-based compensation expense; foreign currency gain; deferred FI implementation costs; costs associated with financing events; loss on extinguishment of debt; restructuring costs; change in fair value of warrant liabilities, net; and a non-cash equity expense recognized in FI Share. We define non-GAAP net (loss) income as our net (loss) income before stock-based compensation expense; change in fair value of warrant liabilities; change in fair value of convertible promissory notes; foreign currency gain; loss on extinguishment of debt; restructuring costs; and costs associated with financing events. Notably, any impacts related to minimum FI Share commitments in connection with agreements with certain FI partners are not added back to net loss in order to calculate adjusted EBITDA. We define non-GAAP net (loss) income per share as non-GAAP net (loss) income divided by our weighted-average common shares outstanding, diluted.

We believe the use of non-GAAP financial measures, as a supplement to GAAP measures, is useful to investors in that they eliminate items that are either not part of our core operations or do not require a cash outlay, such as stock-based compensation expense. Management uses these non-GAAP financial measures when evaluating operating performance and for internal planning and forecasting purposes. We believe that these non-GAAP financial measures help indicate underlying trends in the business, are important in comparing current results with prior period results, and are useful to investors and financial analysts in assessing operating performance.

We define FI MAUs as targetable customers or accounts of our FI partners that logged in and visited the online or mobile banking applications of, or opened an email containing our offers from, our FI partners during a monthly period. We then calculate a monthly average of these FI MAUs for the periods presented. We define ARPU as the total Cardlytics platform revenue generated in the applicable period calculated in accordance with GAAP, divided by the average number of FI MAUs in the applicable period.


CARDLYTICS, INC.
CONSOLIDATED BALANCE SHEETS
(Amounts in thousands)

December 31,

2020

2019

Assets

Current assets:

Cash and cash equivalents

$

293,239

$

104,458

Restricted cash

110

129

Accounts receivable, net

81,249

81,452

Other receivables

5,306

3,908

Prepaid expenses and other assets

5,687

5,783

Total current assets

385,591

195,730

Long-term assets:

Property and equipment, net

13,865

14,290

Right-of-use assets under operating leases, net

10,764

Intangible assets, net

447

389

Capitalized software development costs, net

6,299

3,815

Deferred FI implementation costs, net

3,785

8,383

Other long-term assets, net

1,786

1,706

Total assets

$

422,537

$

224,313

Liabilities and stockholders' equity

Current liabilities:

Accounts payable

$

1,363

$

1,229

Accrued liabilities:

Accrued compensation

7,582

8,186

Accrued expenses

5,502

6,018

FI Share liability

37,457

41,956

Consumer Incentive liability

24,290

19,861

Deferred revenue

349

1,127

Current operating lease liabilities

4,718

Current finance lease liabilities

13

24

Total current liabilities

81,274

78,401

Long-term liabilities:

Convertible senior notes, net

174,011

Deferred liabilities

2,632

Long-term operating lease liabilities

9,381

Long-term finance lease liabilities

13

Other long-term liabilities

679

Total liabilities

265,345

81,046

Stockholders’ equity:

Common stock

8

8

Additional paid-in capital

551,429

480,578

Accumulated other comprehensive (loss) income

(192

)

1,312

Accumulated deficit

(394,053

)

(338,631

)

Total stockholders’ equity

157,192

143,267

Total liabilities and stockholders’ equity

$

422,537

$

224,313


CARDLYTICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands except per share amounts)

Three Months Ended December 31,

Year Ended December 31,

2020

2019

2020

2019

Revenue

$

67,082

$

69,293

$

186,892

$

210,430

Costs and expenses:

FI Share and other third-party costs

38,388

38,986

109,308

118,080

Delivery costs

3,907

3,207

14,310

12,893

Sales and marketing expense

12,503

12,370

45,307

43,828

Research and development expense

5,087

2,958

17,532

11,699

General and administration expense

11,297

9,162

46,532

36,720

Depreciation and amortization expense

2,017

1,354

7,826

4,535

Total costs and expenses

73,199

68,037

240,815

227,755

Operating (loss) income

(6,116

)

1,256

(53,923

)

(17,325

)

Other (expense) income:

Interest (income) expense, net

(3,039

)

312

(3,048

)

(548

)

Other income

2,378

1,859

1,549

729

Total other (expense) income

(661

)

2,171

(1,499

)

181

Income (loss) before income taxes

(6,777

)

3,427

(55,422

)

(17,144

)

Income tax benefit

Net (loss) income

(6,777

)

3,427

(55,422

)

(17,144

)

Net (loss) income attributable to common stockholders

$

(6,777

)

$

3,427

$

(55,422

)

$

(17,144

)

Net (loss) income per share attributable to common stockholders, basic

$

(0.24

)

$

0.13

$

(2.04

)

$

(0.72

)

Net (loss) income per share attributable to common stockholders, diluted

$

(0.24

)

$

0.12

$

(2.04

)

$

(0.72

)


CARDLYTICS, INC.
STOCK-BASED COMPENSATION EXPENSE
(Amounts in thousands)

Three Months Ended December 31,

Year Ended December 31,

2020

2019

2020

2019

Delivery costs

$

283

$

172

$

1,181

$

711

Sales and marketing expense

2,230

1,157

9,857

4,248

Research and development expense

1,200

415

4,713

1,619

General and administration expense

3,871

1,841

16,645

9,273

Total stock-based compensation expense

$

7,584

$

3,585

$

32,396

$

15,851


CARDLYTICS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands)

Year Ended December 31,

2020

2019

Operating activities

Net loss

$

(55,422

)

$

(17,144

)

Adjustments to reconcile net loss to net cash (used in) provided by operating activities:

Credit loss expense

1,196

1,201

Depreciation and amortization

7,826

4,535

Amortization of financing costs charged to interest expense

312

95

Amortization of right-of-use assets

3,766

Accretion of debt discount and non-cash interest expense

2,486

Stock-based compensation expense

32,396

15,851

Other non-cash expense, net

(1,003

)

(570

)

Amortization and impairment of deferred FI implementation costs

4,598

2,869

Change in operating assets and liabilities:

Accounts receivable

(2,396

)

(26,018

)

Prepaid expenses and other assets

(65

)

(2,224

)

Recovery of deferred FI implementation costs

4,625

Accounts payable

16

(601

)

Other accrued expenses

(1,238

)

6,152

FI Share liability

(4,499

)

14,301

Customer Incentive liability

4,429

8,385

Net cash (used in) provided by operating activities

(7,598

)

11,457

Investing activities

Acquisition of property and equipment

(5,408

)

(8,277

)

Acquisition of patents

(76

)

(31

)

Capitalized software development costs

(4,633

)

(2,712

)

Net cash used in investing activities

(10,117

)

(11,020

)

Financing activities

Principal payments of debt

(23

)

(46,698

)

Proceeds from issuance of convertible senior notes, net of issuance costs paid of $6,900

223,100

Purchase of capped calls related to convertible senior notes

(26,450

)

Proceeds from issuance of common stock

10,185

91,216

Equity issuance costs

(196

)

Debt issuance costs

(382

)

(143

)

Net cash provided by financing activities

206,430

44,179

Effect of exchange rates on cash, cash equivalents and restricted cash

47

101

Net increase in cash, cash equivalents and restricted cash

188,762

44,717

Cash, cash equivalents, and restricted cash — Beginning of period

104,587

59,870

Cash, cash equivalents, and restricted cash — End of period

$

293,349

$

104,587


CARDLYTICS, INC.
SUMMARY OF GAAP AND NON-GAAP RESULTS
(Dollars in thousands)

Three Months Ended
December 31,

Change

Year Ended
December 31,

Change

2020

2019

$

%

2020

2019

$

%

Billings(1)

$

93,965

$

100,935

$

(6,970

)

(7

)%

$

263,355

$

316,053

$

(52,698

)

(17

)%

Consumer Incentives

26,883

31,642

(4,759

)

(15

)

76,463

105,623

(29,160

)

(28

)

Revenue

67,082

69,293

(2,211

)

(3

)

186,892

210,430

(23,538

)

(11

)

Adjusted FI Share and other third-party costs(1)

37,430

38,290

(860

)

(2

)

104,710

115,211

(10,501

)

(9

)

Adjusted contribution(1)

29,652

31,003

(1,351

)

(4

)

82,182

95,219

(13,037

)

(14

)

Delivery costs

3,907

3,207

700

22

14,310

12,893

1,417

11

Deferred FI implementation costs(2)

958

696

262

38

4,598

2,869

1,729

60

Gross profit

$

24,787

$

27,100

$

(2,313

)

(9

)%

$

63,274

$

79,457

$

(16,183

)

(20

)%

(1) Billings, adjusted FI share and other third-party costs and adjusted contribution are non-GAAP measures. Reconciliations of these non-GAAP measures to the most comparable GAAP measures are presented below under the headings "Reconciliation of GAAP Revenue to Billings" and "Reconciliation of GAAP Gross Profit to Adjusted Contribution."
(2) Deferred FI implementation costs for the year ended December 31, 2020 includes the impact of a $0.7 million write off related to certain platform features.


CARDLYTICS, INC.
RECONCILIATION OF GAAP REVENUE TO BILLINGS
(Amounts in thousands)

Three Months Ended
December 31,

Year Ended December 31,

2020

2019

2020

2019

Revenue

$

67,082

$

69,293

$

186,892

$

210,430

Plus:

Consumer Incentives

26,883

31,642

76,463

105,623

Billings

$

93,965

$

100,935

$

263,355

$

316,053


CARDLYTICS, INC.
RECONCILIATION OF GAAP GROSS PROFIT TO ADJUSTED CONTRIBUTION
(Amounts in thousands)

Three Months Ended
December 31,

Year Ended December 31,

2020

2019

2020

2019

Revenue

$

67,082

$

69,293

$

186,892

$

210,430

Minus:

FI Share and other third-party costs

38,388

38,986

109,308

118,080

Delivery costs(1)

3,907

3,207

14,310

12,893

Gross profit

24,787

27,100

63,274

79,457

Plus:

Delivery costs(1)

3,907

3,207

14,310

12,893

Deferred FI implementation costs(2)

958

696

4,598

2,869

Adjusted contribution

$

29,652

$

31,003

$

82,182

$

95,219

(1) Stock-based compensation expense recognized in delivery costs totaled $0.2 million and $0.3 million during the three months ended December 31, 2019 and 2020, respectively. Stock-based compensation expense recognized in delivery costs totaled $0.7 million and $1.2 million during the year ended December 31, 2019 and 2020, respectively.
(2) Non-cash equity expense included in FI Share and other third-party costs and deferred FI implementation costs are excluded from adjusted FI Share and other third party costs as shown below (in thousands):

Three Months Ended
December 31,

Year Ended December 31,

2020

2019

2020

2019

FI Share and other third-party costs

$

38,388

$

38,986

$

109,308

$

118,080

Minus:

Deferred FI implementation costs(1)

958

696

4,598

2,869

Adjusted FI Share and other third-party costs

$

37,430

$

38,290

$

104,710

$

115,211






(1) Deferred FI implementation costs for the year ended December 31, 2020 includes the impact of a $0.7 million write off related to certain platform features.



CARDLYTICS, INC.
RECONCILIATION OF GAAP NET (LOSS) INCOME TO ADJUSTED EBITDA
(Amounts in thousands)

Three Months Ended
December 31,

Year Ended December 31,

2020

2019

2020

2019

Net (loss) income

$

(6,777

)

$

3,427

$

(55,422

)

$

(17,144

)

Plus:

Income tax benefit

Interest expense (income), net

3,039

(312

)

3,048

548

Depreciation and amortization

2,017

1,354

7,826

4,535

Stock-based compensation expense

7,584

3,585

32,396

15,851

Foreign currency gain

(2,377

)

(1,859

)

(1,549

)

(781

)

Deferred FI implementation costs

958

696

4,598

2,869

Costs associated with financing events

123

Loss on extinguishment of debt

51

Restructuring costs

47

1,323

Adjusted EBITDA

$

4,491

$

6,891

$

(7,780

)

$

6,052


CARDLYTICS, INC.
RECONCILIATION OF GAAP NET (LOSS) INCOME TO NON-GAAP NET (LOSS) INCOME AND NON-GAAP NET (LOSS) INCOME PER SHARE
(Amounts in thousands except per share amounts)

Three Months Ended December 31,

Year Ended December 31,

2020

2019

2020

2019

Net (loss) income

$

(6,777

)

$

3,427

$

(55,422

)

$

(17,144

)

Plus:

Stock-based compensation expense

7,584

3,585

32,396

15,851

Foreign currency gain

(2,377

)

(1,859

)

(1,549

)

(781

)

Loss on extinguishment of debt

51

Restructuring costs

47

1,323

Costs associated with financing events

123

Non-GAAP net (loss) income

(1,523

)

5,153

(23,252

)

(1,900

)

Weighted-average number of shares of common stock used in computing non-GAAP net (loss) income per share:

GAAP weighted-average common shares outstanding, diluted

27,705

28,083

27,231

23,746

Non-GAAP net (loss) income per share, diluted

$

(0.05

)

$

0.18

$

(0.85

)

$

(0.08

)


CARDLYTICS, INC.
RECONCILIATION OF FORECASTED GAAP REVENUE TO BILLINGS
(Amounts in millions)

Q1 2021 Guidance

FY 2021 Guidance

Revenue

$47.0 - $53.0

$250.0 - $275.0

Plus:

Consumer Incentives

$20.0 - $22.0

$110.0 - $125.0

Billings

$67.0 - $75.0

$360.0 - $400.0


Contacts:

Public Relations:

ICR
cardlyticspr@icrinc.com

Investor Relations:

William Maina
ICR, Inc.
(646) 277-1236
ir@cardlytics.com



Advertisement